Teladoc’s (TDOC) Buy Rating Reaffirmed at KeyCorp

KeyCorp reaffirmed their buy rating on shares of Teladoc (NYSE:TDOC) in a research note released on Wednesday morning. The firm currently has a $41.00 target price on the health services provider’s stock. KeyCorp also issued estimates for Teladoc’s Q4 2017 earnings at ($0.31) EPS, FY2017 earnings at ($1.46) EPS, Q1 2018 earnings at ($0.36) EPS, Q2 2018 earnings at ($0.19) EPS, Q3 2018 earnings at ($0.18) EPS, Q4 2018 earnings at ($0.20) EPS, FY2018 earnings at ($0.93) EPS and FY2019 earnings at ($0.75) EPS.

A number of other equities analysts have also recently issued reports on TDOC. Robert W. Baird cut Teladoc from an outperform rating to a neutral rating and increased their price target for the stock from $14.00 to $36.00 in a report on Monday, September 18th. Zacks Investment Research raised Teladoc from a sell rating to a hold rating in a research report on Thursday, September 21st. Cantor Fitzgerald reaffirmed a hold rating and set a $31.00 target price on shares of Teladoc in a research report on Tuesday, September 26th. Piper Jaffray Companies reaffirmed a buy rating and set a $42.00 target price on shares of Teladoc in a research report on Friday, September 29th. Finally, Cowen reaffirmed an outperform rating and set a $39.00 target price on shares of Teladoc in a research report on Saturday, September 30th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and eleven have assigned a buy rating to the company. The stock has a consensus rating of Buy and an average price target of $39.31.

Teladoc (NYSE:TDOC) traded down $0.55 during trading on Wednesday, hitting $32.65. The company’s stock had a trading volume of 1,905,336 shares, compared to its average volume of 1,170,000. The company has a market cap of $1,980.00 and a PE ratio of -22.52. Teladoc has a 52-week low of $15.65 and a 52-week high of $38.40. The company has a debt-to-equity ratio of 0.83, a current ratio of 5.08 and a quick ratio of 5.08.

Teladoc (NYSE:TDOC) last posted its quarterly earnings results on Wednesday, November 1st. The health services provider reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.25). The business had revenue of $68.70 million for the quarter, compared to the consensus estimate of $67.53 million. Teladoc had a negative return on equity of 21.59% and a negative net margin of 39.61%. Teladoc’s quarterly revenue was up 112.0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.33) earnings per share. sell-side analysts expect that Teladoc will post -1.58 earnings per share for the current fiscal year.

In related news, CEO Jason N. Gorevic sold 100,000 shares of the stock in a transaction on Monday, December 4th. The stock was sold at an average price of $32.99, for a total value of $3,299,000.00. Following the completion of the sale, the chief executive officer now directly owns 718,261 shares of the company’s stock, valued at approximately $23,695,430.39. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Mark Hirschhorn sold 25,000 shares of the stock in a transaction on Monday, October 16th. The shares were sold at an average price of $32.37, for a total value of $809,250.00. Following the completion of the sale, the chief financial officer now directly owns 20,887 shares of the company’s stock, valued at $676,112.19. The disclosure for this sale can be found here. Insiders sold a total of 210,000 shares of company stock valued at $6,889,350 over the last three months. 4.47% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. ETF Managers Group LLC purchased a new stake in Teladoc in the 2nd quarter valued at $104,000. Pacad Investment Ltd. purchased a new stake in Teladoc in the 2nd quarter valued at $135,000. Fred Alger Management Inc. purchased a new stake in Teladoc in the 2nd quarter valued at $139,000. Ameritas Investment Partners Inc. raised its position in Teladoc by 134.2% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,724 shares of the health services provider’s stock valued at $164,000 after buying an additional 2,707 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. purchased a new stake in Teladoc in the 2nd quarter valued at $166,000.

ILLEGAL ACTIVITY WARNING: “Teladoc’s (TDOC) Buy Rating Reaffirmed at KeyCorp” was first published by BBNS and is owned by of BBNS. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The original version of this piece can be viewed at https://baseballnewssource.com/markets/teladocs-tdoc-buy-rating-reaffirmed-at-keycorp/1832701.html.

Teladoc Company Profile

Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.

Analyst Recommendations for Teladoc (NYSE:TDOC)

Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with our FREE daily email newsletter.

 


Latest News

Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
MLB Rumor: Pirates Discussing Andrew McCutchen with Mets
Trade Rumor: Manny Machado Could Land With Yankees
Trade Rumor: Manny Machado Could Land With Yankees
Los Angeles Dodgers Acquire Scott Alexander as Part of Three Team Deal
Los Angeles Dodgers Acquire Scott Alexander as Part of Three Team Deal
Rumor: Braves Show Interest in Reamluto, Yelich
Rumor: Braves Show Interest in Reamluto, Yelich


Leave a Reply

 
© 2006-2018 BBNS.